Development and validation of a novel non‐invasive test for diagnosing fibrotic non‐alcoholic steatohepatitis in patients with biopsy‐proven non‐alcoholic fatty liver disease

Background and Aim There is an immediate need for non‐invasive accurate tests for diagnosing liver fibrosis in patients with non‐alcoholic steatohepatitis (NASH). Previously, it has been suggested that MACK‐3 (a formula that combines homeostasis model assessment‐insulin resistance with serum serum a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2020-10, Vol.35 (10), p.1804-1812
Main Authors: Gao, Feng, Huang, Jiao‐Feng, Zheng, Kenneth I., Pan, Xiao‐Yan, Ma, Hong‐Lei, Liu, Wen‐Yue, Byrne, Christopher D., Targher, Giovanni, Li, Yang‐Yang, Chen, Yong‐Ping, Chan, Wah‐Kheong, Zheng, Ming‐Hua
Format: Article
Language:English
Subjects:
Aspartate aminotransferase
Biopsy
Cytokeratin
diagnostic tests
Fatty liver
Fibrosis
Homeostasis
Insulin
liver biopsy
Liver diseases
liver fibrosis
Metabolic syndrome
NAFLD, clinical
NASH
Platelets
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim There is an immediate need for non‐invasive accurate tests for diagnosing liver fibrosis in patients with non‐alcoholic steatohepatitis (NASH). Previously, it has been suggested that MACK‐3 (a formula that combines homeostasis model assessment‐insulin resistance with serum serum aspartate aminotransferase and cytokeratin [CK]18‐M30 levels) accurately identifies patients with fibrotic NASH. Our aim was to assess the performance of MACK‐3 and develop a novel, non‐invasive algorithm for diagnosing fibrotic NASH. Methods Six hundred and thirty‐six adults with biopsy‐proven non‐alcoholic fatty liver disease (NAFLD) from two independent Asian cohorts were enrolled in our study. Liver stiffness measurement (LSM) was assessed by vibration‐controlled transient elastography (Fibroscan). Fibrotic NASH was defined as NASH with a NAFLD activity score (NAS) ≥ 4 and F ≥ 2 fibrosis. Results Metabolic syndrome (MetS), platelet count and MACK‐3 were independent predictors of fibrotic NASH. On the basis of their regression coefficients, we developed a novel nomogram showing a good discriminatory ability (area under receiver operating characteristic curve [AUROC]: 0.79, 95% confidence interval [CI 0.75–0.83]) and a high negative predictive value (NPV: 94.7%) to rule out fibrotic NASH. In the validation set, this nomogram had a higher AUROC (0.81, 95%CI 0.74–0.87) than that of MACK‐3 (AUROC: 0.75, 95%CI 0.68–0.82; P 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.15055